The UK's MHRA unveiled a 2030 regulatory strategy built around AI and personalised medicine, promising faster trial reviews, a new AI and Digital Health centre, and closer alignment with the FDA on device recognition.
Google's new Health Guardian AI suite brings passive blood pressure and insulin resistance trend tracking to Fitbit Air, but the most useful features require a $9.99-a-month subscription, raising questions about equitable access to early health warnings.
Apollo Hospitals in India is using AI to read stroke brain scans in about two minutes instead of an hour, even as regulators move to classify diagnostic AI tools as higher-risk medical devices.
Eli Lilly signed a deal worth up to $2.25 billion with AI gene-editing company Profluent, extending its aggressive multi-platform bet on AI drug discovery across several distinct technology approaches.
AI drug discovery company Iambic Therapeutics completed a $150 million IPO with shares rising, showing investor appetite for AI-native biotechs even as the sector awaits its first approved medicine.
Swedish digital health provider Yazen's $56 million round, led by Verdane, shows continued European investor appetite for technology-enabled care models amid aging populations.
OpenAI says 230 million people ask ChatGPT health questions weekly, as its dedicated Health feature expands to pull records from One Medical, Kaiser Permanente and Apple Health — raising questions about AI's growing role in informal medical advice.
Quebec startup Bia Health raised C$2.15 million to expand an AI assistant that helps clinicians avoid unnecessary imaging and referrals, targeting the roughly 30% of Canadian healthcare spending estimated to go toward low-value care.
OpenEvidence and Johns Hopkins Medicine will jointly redesign medical training and clinical decision-support tools for the AI era, extending OpenEvidence's reach into major academic health systems weeks after a similar deal with Penn Medicine.
Healthleap raised $38 million after growing from three to more than 50 hospital customers in a year, betting that an AI tool which mines clinical notes for missed diagnoses can prove hard financial ROI, not just clinical promise.